07.16.26 -- Fundamentals Over Factors: How To Select Your CDMO

Discover how surging demand for GLP-1 and other therapeutics is transforming fill/finish capacity and regulatory standards. Learn how CDMOs are adapting to the complex needs of emerging modalities.

Global partner delivering end‑to‑end drug development, manufacturing, and packaging with deep expertise, advanced facilities, and support across key modalities.

A multi-stage filtration approach reduces microbial load, protects critical filters, and helps ensure consistent product quality, process reliability, and patient safety in biopharmaceutical manufacturing.

Modern injectable programs require adaptable manufacturing strategies. Learn how flexibility, technical depth, and collaboration reduce complexity, manage change, and protect long‑term supply.

ADCs have emerged as a promising class of targeted cancer therapies. Explore linker-payload design elements, conjugation and characterization of ADCs, and the different bioassays used to screen ADCs.

Assimilate how to build a resilient supply chain to navigate today's complex environment. Expert speakers share insights on optimization, innovation, and strategic planning to meet evolving conditions.

Downstream purification is becoming more complex as new modalities enter development. See how advanced analytics and chromatography strategies can support confident process development.

Explore how infrastructure, equipment strategy, and advanced technologies shape a more reliable path for scaling sterile injectable programs.

Standardized, continuously optimized facility design enables efficient and reliable biomanufacturing that improves quality, accelerates timelines, and ensures consistent performance across sites.

Manufacturing excellence drives complex therapies, with scale, speed, supply resilience, sustainability, and future readiness enabling development to reliable commercial production.

Single-use systems improve sterile manufacturing by boosting flexibility, reducing changeovers, and lowering contamination risk—while supporting traditional systems based on scale and process needs.

A streamlined purification strategy is reshaping how microbial biologics move from expression to manufacturing. Uncover how to reduce downstream complexity while preserving native protein integrity.

As bioconjugates evolve, optimized conjugation and strong process and analytical strategies are essential for ensuring consistent quality, targeted characteristics, and reliable therapeutic performance.

Skin delivery platforms expand therapies by boosting convenience, stability, and adherence. Integrated formulation, device, and manufacturing development is key to confidently scale.